The Burden of Inflammatory Bowel Disease in Europe in 2020
Abstract New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, wit...
Gespeichert in:
Veröffentlicht in: | Journal of Crohn's and colitis 2021-09, Vol.15 (9), p.1573-1587 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1587 |
---|---|
container_issue | 9 |
container_start_page | 1573 |
container_title | Journal of Crohn's and colitis |
container_volume | 15 |
creator | Zhao, Mirabella Gönczi, Lóránt Lakatos, Peter L Burisch, Johan |
description | Abstract
New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring of disease progression and a treat-to-target approach in Europe and also worldwide, aiming to prevent early bowel damage and disability. Surgery rate declined over time in Europe, with 10–30% of CD and 5–10% of UC patients requiring a surgery within 5 years. The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region. |
doi_str_mv | 10.1093/ecco-jcc/jjab029 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2489595633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ecco-jcc/jjab029</oup_id><sourcerecordid>2489595633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-14fbe58593ed10f09752606c0d8a7137e79878c6d587d411f720c571c4485d753</originalsourceid><addsrcrecordid>eNptkDtPwzAUhS0EoqWwM6GMSCjUz9hmo6VApUosZbZc50YkSuJiN0L996QPEAPTPcM5n3Q_hK4JvidYszE459PKuXFV2RWm-gQNiZJZyrnUp_vMUq15NkAXMVYYCy2kOkcDxoSiitAhelh-QDLpQg5t4otk3ha1bRq78WGbTPwX1MlTGcFGSMo2mXXBr_eJYoov0Vlh6whXxztC78-z5fQ1Xby9zKePi9RxzjYp4cUKhBKaQU5wgbUUNMOZw7mykjAJUiupXJYLJXNOSCEpdkKSfq1ELgUbodsDdx38ZwdxY5oyOqhr24LvoqFc6f6xjLG-ig9VF3yMAQqzDmVjw9YQbHbGzM6Y6Y2Zo7F-cnOkd6sG8t_Bj6K-cHco-G79Ly79i_sGF9B1CA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2489595633</pqid></control><display><type>article</type><title>The Burden of Inflammatory Bowel Disease in Europe in 2020</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Zhao, Mirabella ; Gönczi, Lóránt ; Lakatos, Peter L ; Burisch, Johan</creator><creatorcontrib>Zhao, Mirabella ; Gönczi, Lóránt ; Lakatos, Peter L ; Burisch, Johan</creatorcontrib><description>Abstract
New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring of disease progression and a treat-to-target approach in Europe and also worldwide, aiming to prevent early bowel damage and disability. Surgery rate declined over time in Europe, with 10–30% of CD and 5–10% of UC patients requiring a surgery within 5 years. The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region.</description><identifier>ISSN: 1873-9946</identifier><identifier>EISSN: 1876-4479</identifier><identifier>DOI: 10.1093/ecco-jcc/jjab029</identifier><identifier>PMID: 33582812</identifier><language>eng</language><publisher>UK: Oxford University Press</publisher><subject>Adult ; Aged ; Colectomy - economics ; Colectomy - statistics & numerical data ; Colitis, Ulcerative - economics ; Colitis, Ulcerative - epidemiology ; Colitis, Ulcerative - therapy ; Cost of Illness ; Crohn Disease - economics ; Crohn Disease - epidemiology ; Crohn Disease - therapy ; Europe - epidemiology ; Female ; Health Care Costs - statistics & numerical data ; Hospitalization - economics ; Hospitalization - statistics & numerical data ; Humans ; Incidence ; Male ; Middle Aged ; Prevalence ; Survival Rate ; Young Adult</subject><ispartof>Journal of Crohn's and colitis, 2021-09, Vol.15 (9), p.1573-1587</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-14fbe58593ed10f09752606c0d8a7137e79878c6d587d411f720c571c4485d753</citedby><cites>FETCH-LOGICAL-c443t-14fbe58593ed10f09752606c0d8a7137e79878c6d587d411f720c571c4485d753</cites><orcidid>0000-0002-8392-4860 ; 0000-0002-3312-5139 ; 0000-0002-3948-6488</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33582812$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Mirabella</creatorcontrib><creatorcontrib>Gönczi, Lóránt</creatorcontrib><creatorcontrib>Lakatos, Peter L</creatorcontrib><creatorcontrib>Burisch, Johan</creatorcontrib><title>The Burden of Inflammatory Bowel Disease in Europe in 2020</title><title>Journal of Crohn's and colitis</title><addtitle>J Crohns Colitis</addtitle><description>Abstract
New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring of disease progression and a treat-to-target approach in Europe and also worldwide, aiming to prevent early bowel damage and disability. Surgery rate declined over time in Europe, with 10–30% of CD and 5–10% of UC patients requiring a surgery within 5 years. The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region.</description><subject>Adult</subject><subject>Aged</subject><subject>Colectomy - economics</subject><subject>Colectomy - statistics & numerical data</subject><subject>Colitis, Ulcerative - economics</subject><subject>Colitis, Ulcerative - epidemiology</subject><subject>Colitis, Ulcerative - therapy</subject><subject>Cost of Illness</subject><subject>Crohn Disease - economics</subject><subject>Crohn Disease - epidemiology</subject><subject>Crohn Disease - therapy</subject><subject>Europe - epidemiology</subject><subject>Female</subject><subject>Health Care Costs - statistics & numerical data</subject><subject>Hospitalization - economics</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>1873-9946</issn><issn>1876-4479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkDtPwzAUhS0EoqWwM6GMSCjUz9hmo6VApUosZbZc50YkSuJiN0L996QPEAPTPcM5n3Q_hK4JvidYszE459PKuXFV2RWm-gQNiZJZyrnUp_vMUq15NkAXMVYYCy2kOkcDxoSiitAhelh-QDLpQg5t4otk3ha1bRq78WGbTPwX1MlTGcFGSMo2mXXBr_eJYoov0Vlh6whXxztC78-z5fQ1Xby9zKePi9RxzjYp4cUKhBKaQU5wgbUUNMOZw7mykjAJUiupXJYLJXNOSCEpdkKSfq1ELgUbodsDdx38ZwdxY5oyOqhr24LvoqFc6f6xjLG-ig9VF3yMAQqzDmVjw9YQbHbGzM6Y6Y2Zo7F-cnOkd6sG8t_Bj6K-cHco-G79Ly79i_sGF9B1CA</recordid><startdate>20210925</startdate><enddate>20210925</enddate><creator>Zhao, Mirabella</creator><creator>Gönczi, Lóránt</creator><creator>Lakatos, Peter L</creator><creator>Burisch, Johan</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8392-4860</orcidid><orcidid>https://orcid.org/0000-0002-3312-5139</orcidid><orcidid>https://orcid.org/0000-0002-3948-6488</orcidid></search><sort><creationdate>20210925</creationdate><title>The Burden of Inflammatory Bowel Disease in Europe in 2020</title><author>Zhao, Mirabella ; Gönczi, Lóránt ; Lakatos, Peter L ; Burisch, Johan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-14fbe58593ed10f09752606c0d8a7137e79878c6d587d411f720c571c4485d753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Colectomy - economics</topic><topic>Colectomy - statistics & numerical data</topic><topic>Colitis, Ulcerative - economics</topic><topic>Colitis, Ulcerative - epidemiology</topic><topic>Colitis, Ulcerative - therapy</topic><topic>Cost of Illness</topic><topic>Crohn Disease - economics</topic><topic>Crohn Disease - epidemiology</topic><topic>Crohn Disease - therapy</topic><topic>Europe - epidemiology</topic><topic>Female</topic><topic>Health Care Costs - statistics & numerical data</topic><topic>Hospitalization - economics</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Mirabella</creatorcontrib><creatorcontrib>Gönczi, Lóránt</creatorcontrib><creatorcontrib>Lakatos, Peter L</creatorcontrib><creatorcontrib>Burisch, Johan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Crohn's and colitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Mirabella</au><au>Gönczi, Lóránt</au><au>Lakatos, Peter L</au><au>Burisch, Johan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Burden of Inflammatory Bowel Disease in Europe in 2020</atitle><jtitle>Journal of Crohn's and colitis</jtitle><addtitle>J Crohns Colitis</addtitle><date>2021-09-25</date><risdate>2021</risdate><volume>15</volume><issue>9</issue><spage>1573</spage><epage>1587</epage><pages>1573-1587</pages><issn>1873-9946</issn><eissn>1876-4479</eissn><abstract>Abstract
New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring of disease progression and a treat-to-target approach in Europe and also worldwide, aiming to prevent early bowel damage and disability. Surgery rate declined over time in Europe, with 10–30% of CD and 5–10% of UC patients requiring a surgery within 5 years. The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region.</abstract><cop>UK</cop><pub>Oxford University Press</pub><pmid>33582812</pmid><doi>10.1093/ecco-jcc/jjab029</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-8392-4860</orcidid><orcidid>https://orcid.org/0000-0002-3312-5139</orcidid><orcidid>https://orcid.org/0000-0002-3948-6488</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1873-9946 |
ispartof | Journal of Crohn's and colitis, 2021-09, Vol.15 (9), p.1573-1587 |
issn | 1873-9946 1876-4479 |
language | eng |
recordid | cdi_proquest_miscellaneous_2489595633 |
source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
subjects | Adult Aged Colectomy - economics Colectomy - statistics & numerical data Colitis, Ulcerative - economics Colitis, Ulcerative - epidemiology Colitis, Ulcerative - therapy Cost of Illness Crohn Disease - economics Crohn Disease - epidemiology Crohn Disease - therapy Europe - epidemiology Female Health Care Costs - statistics & numerical data Hospitalization - economics Hospitalization - statistics & numerical data Humans Incidence Male Middle Aged Prevalence Survival Rate Young Adult |
title | The Burden of Inflammatory Bowel Disease in Europe in 2020 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A27%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Burden%20of%20Inflammatory%20Bowel%20Disease%20in%20Europe%20in%202020&rft.jtitle=Journal%20of%20Crohn's%20and%20colitis&rft.au=Zhao,%20Mirabella&rft.date=2021-09-25&rft.volume=15&rft.issue=9&rft.spage=1573&rft.epage=1587&rft.pages=1573-1587&rft.issn=1873-9946&rft.eissn=1876-4479&rft_id=info:doi/10.1093/ecco-jcc/jjab029&rft_dat=%3Cproquest_cross%3E2489595633%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2489595633&rft_id=info:pmid/33582812&rft_oup_id=10.1093/ecco-jcc/jjab029&rfr_iscdi=true |